68Ga-CD73 PET/CT imaging for diagnosing malignant tumors

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor

This uses a 68Ga-DOTA-dPNE PET/CT scan that targets CD73 to see if it can detect malignant tumors and help predict response to targeted therapies in adults with measurable solid tumors.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Peking Union Medical College Hospital (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Dongcheng, Beijing Municipality)
• Trial ID: NCT06844110 on ClinicalTrials.gov

What this trial studies

Participants with measurable solid tumors receive a 68Ga-DOTA-dPNE PET/CT scan to visualize tracer binding and estimate CD73 expression in lesions. Imaging findings will be compared with pathological samples when surgery or biopsy is available and correlated with clinical indicators to explore links with treatment response. Eligible participants are adults with at least one RECIST 1.1 measurable lesion, expected survival ≥12 weeks, able to undergo biopsy or surgery, and without recent chemotherapy or radiotherapy. The protocol seeks to determine whether this targeted PET probe can improve localization of CD73-expressing tumors and provide information useful for guiding targeted therapy.

Who should consider this trial

Good fit: Ideal candidates are adults (≥18 years) with at least one RECIST 1.1 measurable solid tumor, expected survival ≥12 weeks, who can undergo biopsy or surgery and lie flat for imaging.

Not a fit: Patients with severe liver or kidney dysfunction, pregnant or breastfeeding women, those unable to lie flat or with claustrophobia, or patients whose tumors do not express CD73 are unlikely to benefit.

Why it matters

Potential benefit: If successful, this imaging method could provide a noninvasive way to identify CD73-expressing tumors and help guide selection and prediction of response to targeted treatments.

How similar studies have performed: CD73-targeted PET imaging is relatively novel: preclinical studies support the approach and only limited early clinical imaging data exist, although other immune-targeted PET tracers have shown promise in early studies.

Eligibility criteria

Inclusion Criteria:

* 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up

Exclusion Criteria:

\- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study.

3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study

Where this trial is running

Dongcheng, Beijing Municipality

• PUMCH — Dongcheng, Beijing Municipality, China (RECRUITING)

Study contacts

• Principal investigator: Xianzhong Zhang, PhD — Peking Union Medical College Hospital
• Study coordinator: Chenhao Jia

Conditions: Tumor Immunity